文献速递骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

现代疗法时代黑色素瘤脑转移与软脑膜疾病患者的生存改善:一项全国性研究(2015-2022年)的启示

Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
PubMed 文献 · Eur J Cancer · 2025-01-21

该全国性队列纳入2015至2022年丹麦诊断的838例黑色素瘤脑转移患者,中位总生存9.0个月,112例(19.4%)生存超过3年。一线伊匹木单抗联合纳武利尤单抗的颅内客观缓解率为46%、2年总生存49%;BRAF/MEK抑制剂颅内客观缓解率56%但2年总生存20%。软脑膜疾病患者(n=67)中位总生存8.4个月,全身治疗与更优总生存相关,但ICI与BRAF/MEKi之间未见生存获益差异。

要点

  • 838例黑色素瘤脑转移患者中位总生存9.0个月,112例(19.4%)生存超过3年。
  • 一线伊匹木单抗联合纳武利尤单抗颅内客观缓解率46%、2年总生存49%。
  • 软脑膜疾病患者中位总生存8.4个月,ICI与BRAF/MEKi间未见生存获益差异。

核心结论

  • 2015年后诊断的黑色素瘤脑转移患者中相当比例生存超过3年。
  • 软脑膜疾病患者似乎从ICI中获益有限,仅少数患者诊断后生存超过3年。

研究设计与样本

  • 本研究纳入2015至2022年在丹麦诊断的所有黑色素瘤脑转移患者,通过丹麦转移性黑色素瘤数据库(DAMMED)及本地手术和放疗记录识别,数据来自电子病历。
  • 共纳入838例患者,其中软脑膜疾病患者67例,接受手术者230例。

主要发现

  • 全部患者中位总生存9.0个月,112例(19.4%)诊断后生存超过3年。
  • 一线伊匹木单抗联合纳武利尤单抗治疗者颅内客观缓解率46%、2年总生存49%。
  • BRAF/MEK抑制剂治疗者颅内客观缓解率56%、2年总生存20%。
  • 软脑膜疾病患者(n=67)中位总生存8.4个月,全身治疗与更优总生存相关,但ICI与BRAF/MEKi之间未见生存获益差异。
  • 230例接受手术的患者中30例接受术后立体定向放射外科治疗,两组间总生存或颅内无进展生存未见差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Advances in modern therapies have improved outcomes for patients with melanoma brain metastases (MBM), though prognosis remains poor. The optimal treatment strategy for patients who do not meet clinical trial inclusion criteria is unclear. METHODS: This study included all patients with MBM diagnosed in Denmark between 2015 and 2022, identified through the Danish Metastatic Melanoma Database (DAMMED) and local surgical and radiotherapy records. Data were collected from electronic patient records. RESULTS: A total of 838 patients were included, with a median overall survival (OS) of 9.0 months. Of these, 112 (19.4 %) survived beyond 3 years post-diagnosis. Patients treated with immune checkpoint inhibitors (ICI) as first line treatment, specifically ipilimumab + nivolumab, demonstrated an intracranial overall response rate (icORR) of 46 % and a 2-year OS of 49 %. Those treated with BRAF/MEK inhibitors (BRAF/MEKi) had an icORR of 56 % but a 2-year OS of 20 %. Patients with leptomeningeal disease (LMD, n = 67) had a median OS of 8.4 months. Systemic therapy was associated with a superior OS for patients with LMD, though no survival benefit was seen with ICI compared to BRAF/MEKi. Among the 230 patients who underwent surgery, 30 received postoperative stereotactic radiosurgery (SRS); however, there was no difference in OS or intracranial progression-free survival between the groups. CONCLUSION: A considerable proportion of patients with brain metastases diagnosed after 2015 survived more than 3 years. Patients with LMD appeared to obtain limited benefit of ICI with only few patients alive > 3 years post-diagnosis.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Pedersen S, Johansen EL, Højholt KL, et al. Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022). Eur J Cancer. 2025. PMID: 39874911. doi:10.1016/j.ejca.2025.115253

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。